Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06785636 · ClinicalTrials.gov registry record · Phase 1
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
A Phase 1 study of Prostate Cancer and Neoplasms, sponsored by Pathos AI.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 252
- Enrollment target
- 10
- Study locations
NCT06785636: Recruiting Phase 1 study of Prostate Cancer and Neoplasms, sponsored by Pathos AI.
NCT06785636 is a Phase 1 study of Prostate Cancer and Neoplasms that is actively recruiting participants, run by Pathos AI. The registered enrollment target is 252 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (59% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06785636, a Phase 1 study of Prostate Cancer and Neoplasms, is actively recruiting participants, sponsored by Pathos AI.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 252 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostrate cancer (mCRPC).
Primary Outcome
Occurrence and severity of Serious Adverse Events (SAEs) and clinically relevant Adverse Events (AEs), and clinically significant changes in safety laboratory values and electrocardiograms (ECGs)
Conditions Studied
Interventions
- DRUG Pocenbrodib
- DRUG Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617
Study Locations (10)
Texas
- University of Texas Southwestern Medical Center - Dallas
- Oncology Consultants, P.A - Houston
California
- MemorialCare Orange Coast Medical Center - Fountain Valley
Colorado
- University of Colorado Health - Aurora
Florida
- Mount Sinai Medical Center - Miami
Michigan
- Karmanos Cancer Institute - Detroit
Missouri
- Siteman Cancer Center - St Louis
Nebraska
- Nebraska Cancer Specialists - Omaha
North Carolina
- Duke University medical center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 1 |
What NCT06785636 shows while recruiting
NCT06785636 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (59% lower).
The record links to 10 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pocenbrodib is the first listed.
NCT06785636 lists 10 locations in 9 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06785636 about?
NCT06785636 is a clinical study titled "Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617". This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostrate cancer (mCRPC).
What is the current status of trial NCT06785636?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2025-02-07. Estimated completion is 2029-04-30.
What conditions does trial NCT06785636 study?
This clinical trial studies the following conditions: Prostate Cancer, Neoplasms, Prostatic Neoplasms, Neoplasms by Site, Urogenital Neoplasms.
What interventions are being tested in trial NCT06785636?
The interventions under investigation include: Pocenbrodib (DRUG), Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617 (DRUG).
Who is sponsoring clinical trial NCT06785636?
This trial is sponsored by Pathos AI, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06785636 being conducted?
This trial has 10 study locations across California, Colorado, Florida, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06785636's enrollment target sits among peer trials
252 184th of 735 higher than 552 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI